Plain-English translation of NCT06804590 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new bone-strengthening injection called in postmenopausal women with osteoporosis (weak bones). The study will compare this new medication with an already-approved similar injection called Prolia to see if the treatment works equally well at strengthening bones and is safe to use.
Osteoporosis affects millions of postmenopausal women, putting them at risk for fractures from minor falls or injuries. This medication aims to give women another effective treatment option for strengthening their bones and preventing breaks.
You likely qualify if…
You likely don't qualify if…
If you qualify and join this trial, you will be randomly assigned to receive either the new injection or the approved medication. You will receive injections every 6 months for a total of 12 months (two injections). During the study, your bone density will be measured with a scanning test, and your health will be monitored to ensure the treatment is working and is safe.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Enrollment target
~278 participants
Started
November 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
50 Years – 80 Years
Sex
Female only
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhitian Hu
Mabwell (Shanghai) Bioscience Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.